Piper Jaffray downgraded INSYS Therapeutics (NASDAQ: INSY) from Overweight to Neutral with a price target of $10.00 (from $20.00).Analyst David ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE